In Brief: Bristol-Myers Squibb Serzone
Executive Summary
Bristol-Myers Squibb Serzone: Company commences $20 mil., multi-center, chronic depression treatment study involving 660 patients comparing the safety and efficacy of nefazodone HC1 with cognitive behavior therapy. "Serzone and CBT-CD will be evaluated separately and in combination during acute and continuation treatment of patients with chronic major depression and double depression," Bristol says. The study will also include a one-year maintenance treatment phase comparing Serzone to placebo in the maintenance of clinical response...